ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Investigating the impact of white matter hyperintensities on longitudinal progression in progressive supranuclear palsy.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhite matter hyperintensities (WMH), traditionally linked to cerebral small vessel disease, are frequent in Progressive Supranuclear Palsy (PSP). This study assessed their prognostic value in disease progression.
methodsSixty PSP patients underwent 3 Tesla Magnetic Resonance Imaging (MRI) at baseline and then were followed for of 48.62 ± 25.11 (mean ± standard deviation) months with extensive neurological evaluations. WMH were rated with the age-related white matter changes (ARWMC) scale (total and lobar), classifying patients into two groups: ARWMC = 0 (without WMH) and ARWMC >0 (with WMH). Outcomes included time to disease milestones (unintelligible speech, wheelchair dependency, PEG placement, death). Kaplan-Meier, Cox regression, and linear mixed models were applied, adjusting for age, sex, and vascular risk factors.
resultsBaseline WMH were present in 65% (mean ARWMC score 4.7 ± 3.3), predominantly in frontal and parietal lobes. The presence of WMH did not significantly influence time to milestones or death. In subregional analyses, higher temporal lobe WMH scores predicted reaching any milestones (HR 3.336, 95% CI 1.698-6.555, p<0.001) and death (HR 2.533, 95% CI 1.297-4.945, p=0.006), even after adjusting for age, sex and ARWMC score of all lobes. No effect of WMH burden on PSP-rs progression was observed.
conclusionsOverall WMH burden at baseline was not associated with clinical progression in PSP, although temporal lobe WMH may represent a specific prognostic marker. These findings suggest a limited role of WMH in PSP progression and call for advanced imaging studies to clarify their contribution.
Indexed as
Identifiers
41107578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.